Literature DB >> 6949849

Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel.

D Rachmilewitz, M Ligumsky, A Haimovitz, A J Treves.   

Abstract

Prostanoid synthesis by cultured peripheral blood mononuclear cells and monocytes in inflammatory bowel disease patients was determined because monocytosis was reported in inflammatory bowel diseases and prostanoids are synthesized by peripheral blood mononuclear cells in response to inflammatory stimuli. Prostaglandin E2 and thromboxane B2 accumulation in the medium of cultured peripheral blood mononuclear cells isolated from patients with active Crohn's disease was two and three times higher than their respective accumulation by peripheral blood mononuclear cells isolated from normal subjects or patients in remission. In ulcerative colitis, prostaglandin E2 and thromboxane B2 accumulation was not enhanced. 6-Keto-prostaglandin F1 alpha was not detected in any of the cultured medium. The absolute number of monocytes was determined according to their adherence to plastic surfaces, and the percent of phagocytic cells was significantly higher among peripheral blood mononuclear cells in patients with Crohn's disease and ulcerative colitis as compared with peripheral blood mononuclear cells isolated from normal subjects. However, prostaglandin E2 secretion, by the same number of cultured monocytes isolated from all groups of patients, was similar. Flufenamic acid, methylprednisolone, and 5-aminosalicylic acid significantly inhibited prostaglandin E2 and thromboxane B2 accumulation. These results suggest that in Crohn's disease enhanced prostanoid synthesis is probably due to the monocytosis, whereas in ulcerative colitis the monocytosis is not accompanied by a significant increase in prostanoid synthesis in vitro.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6949849

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  Monocyte zinc and in vitro prostaglandin E2 and interleukin-1 beta production by cultured peripheral blood monocytes in patients with Crohn's disease.

Authors:  H F Goode; B J Rathbone; J Kelleher; B E Walker
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

Review 3.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

4.  Phospholipase A2 activating protein and idiopathic inflammatory bowel disease.

Authors:  J W Peterson; W D Dickey; S S Saini; W Gourley; G R Klimpel; A K Chopra
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

Review 5.  Prostaglandins and ulcerative colitis.

Authors:  D S Rampton; C J Hawkey
Journal:  Gut       Date:  1984-12       Impact factor: 23.059

6.  Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis.

Authors:  L Ferraris; F Karmeli; R Eliakim; J Klein; C Fiocchi; D Rachmilewitz
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

Review 7.  Macrophage activation, chronic inflammation and gastrointestinal disease.

Authors:  A R Tanner; M J Arthur; R Wright
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

8.  Imbalance of prostacyclin and thromboxane synthesis in Crohn's disease.

Authors:  C J Hawkey; F Karmeli; D Rachmilewitz
Journal:  Gut       Date:  1983-10       Impact factor: 23.059

9.  Indomethacin-induced intestinal ulcers in rats: effects of salicylazosulfapyridine and dexamethasone.

Authors:  P Del Soldato; D Foschi; L Varin; S Daniotti
Journal:  Agents Actions       Date:  1985-07

10.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.